USDA grants conditional license to Zoetis for canine anti-itch therapy

Zoetis ($ZTS) has received a conditional license from the U.S. Department of Agriculture for its antibody therapy to treat atopic dermatitis in dogs.

The therapy, called Canine Atopic Dermatitis Immunotherapeutic, uses antibodies that specifically target and neutralize interleukin-31, which is a key protein that triggers the itch signal to the brain, the company said in a press release. The treatment is administered as once-a-month subcutaneous injection and provides relief from itching to dogs of any age.

The regulatory agency has said at the current time, all biological products used to treat canine dermatitis are to be considered only for conditional licensure, but Zoetis said it is working the the USDA to obtain full licensure.

"By helping to relieve itching and the clinical signs associated with atopic dermatitis in affected dogs, it will also help restore quality of life for both atopic dogs and the people who love them," Thomas Lewis II, a veterinarian who participated in the clinical studies for the treatment, said in a statement.

Atopic dermatitis is one of the most frequent complaints of pet owners, the company said, affecting about one in 6 dogs whose owners seek veterinary help. The itching can be triggered by a number of factors, including infections, otitis and parasites. Between 15% and 20% of itchy dogs are typically diagnosed with atopic dermatitis.

- see the release

Suggested Articles

The United Nations’ 2030 Agenda for Sustainable Development lays out a host of priorities including “food security and nutrition,” an ambitious plan to…

Starting next year, drugmakers that market antibiotics for food animals will face tough new FDA rules limiting their use. So now some pharma companies are…

The USDA plans to hold manufacturers of veterinary biotech drugs to new, strict standards on labeling. Although companies will have between four and six years…